ArticleJournal of inflammation research2026
Platelet-Derived LGALS9 Suppresses NLRP3 Inflammasome-Dependent Pyroptosis in Pancreatic Acinar Cells During Severe Acute Pancreatitis.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pyroptosis is a significant contributor to the development of severe acute pancreatitis (SAP), and the presence of SAP together with a reduced platelet count often indicates a poor prognosis. In this study, we screened targets from platelets and explored the role of lectin galactoside-binding soluble 9 (LGALS9) in acinar cell pyroptosis and inflammation in SAP. Methods: SAP cell models, alongside mouse models showing diminished platelet counts, were established using caerulein and lipopolysaccharide. We conducted transcriptomic sequencing on platelets from mice with and without SAP to identify possible targets, and we determined LGALS9 levels in platelet releasates and serum from both patients and mice with and without SAP. Bioinformatic analysis was then applied to predict the relationship between LGALS9 and pyroptosis-related proteins. Subsequently, recombinant LGALS9, α-lactose, and RG9-35 were used to treat SAP mice and acinar cells to evaluate the effect of LGALS9 on inflammation and its regulatory effects on acinar cell pyroptosis in SAP. Results: LGALS9 expression was upregulated in SAP platelets, and LGALS9 levels were found to be significantly elevated in platelet releasates and serum. Bioinformatic analysis illustrated the correlations and interactions between LGALS9 and the pyroptosis-related proteins ASC, NLRP3, caspase-1, and gasdermin D. Within the SAP context, LGALS9 may be potentially administered to diminish acinar cell pyroptosis-related protein levels, inhibit acinar cell pyroptosis, mitigate inflammatory factor levels, and alleviate pancreatic tissue inflammatory damage. Conclusion: Our data indicated that LGALS9 expression was elevated in platelets of patients and mice with SAP. LGALS9 also inhibited NLRP3 inflammasome-dependent pyroptosis and suppressed inflammation in SAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.